The restructuring removes near-term liquidity risk and the change-of-control overhang, but adds ~61M shares of dilution (12.9M common + 48.1M pre-funded warrants) plus 10.4M additional warrants at $0.10-$1.00. Watch for LOTIS-5 topline data in Q4 2026, which is the next binary catalyst. The HCR buyout option at 1.75x suggests management sees a path to significant revenue growth before 2029.
Price Chart
Executive Summary
ADC Therapeutics announced a comprehensive capital restructuring: an $86.6M PIPE (12.9M shares at $1.42 + 48.1M pre-funded warrants at $1.32), a $70M term loan prepayment reducing Blue Owl debt to $50M with no amortization until 2029, and an HCR royalty amendment eliminating the $150M change-of-control payment and reducing warrant exercise prices to $0.10. The PIPE extends cash runway into 2029. Preliminary Q3 2026 ZYNLONTA revenue of ~$21.0M and cash of $189.2M were also disclosed.
Key Financial Metrics
Key Facts
- $86.6M PIPE priced at $1.42/share + pre-funded warrants at $1.32, closing Oct 22, 2026
- $70M term loan prepaid; remaining $50M Blue Owl debt bullet at Aug 2029 maturity, no amortization, no minimum liquidity covenant
- HCR Amendment eliminates $150M change-of-control payment; buyout option set at 1.75x ($525M) if exercised by Dec 2029, 2.5x ($750M) thereafter
- HCR warrants (9.8M shares) exercise price reduced from $3.8130 to $0.10; Lender warrants (527K shares) reduced from $8.30 to $1.00
- Preliminary Q3 2026 ZYNLONTA net product revenue ~$21.0M; cash $189.2M; pro forma cash ~$196M after PIPE and debt paydown
- Expected cash runway extended into 2029; LOTIS-5 topline data anticipated Q4 2026
Financial Impact
$86.6M gross PIPE proceeds; $70M debt paydown; $50M remaining term loan; $525M-$750M HCR buyout option; ~$21.0M Q3 2026 revenue
Risk Factors
- Massive dilution: ~61M new shares from PIPE + 10.4M warrants at deep out-of-the-money strike prices
- LOTIS-5 trial risk — topline data expected Q4 2026 could disappoint
- HCR royalty obligations remain until Royalty Cap; buyout option is expensive ($525M-$750M)
- Redomiciliation to Delaware requires shareholder approval and may face legal/tax hurdles
- Minimum ZYNLONTA sales covenant of $65M trailing four quarters remains in place
Investment Themes
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000950103-26-015465 |
| Document: dp254756_ex1003.htm | 0000950103-26-015465 |
| Document: dp254756_ex1002.htm | 0000950103-26-015465 |
| Document: dp254756_ex1005.htm | 0000950103-26-015465 |
| Document: dp254756_8k.htm | 0000950103-26-015465 |
| Document: dp254756_ex9901.htm | 0000950103-26-015465 |
| Document: dp254756_ex1004.htm | 0000950103-26-015465 |
| Document: 0000950103-26-015465-index-headers.html | 0000950103-26-015465 |
| 8-K Data (Synthetic) | 0000950103-26-015465 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 14d ago | 8-K | $1.70 $1.52 | ▼ −10.59% | ▼ −9.44% | $1.59 (−6.47%) |
Aug 6, 2026 11w ago | Press Release | $1.13 $1.05 | ▼ −7.08% | ▼ −8.29% | $1.59 (+40.71%) |
Jul 2, 2026 16w ago | 8-K | $1.19 $1.30 | ▲ +9.24% | ▲ +8.31% | $1.59 (+33.61%) |
Jun 3, 2026 20w ago | 8-K | $1.32 $1.06 | ▼ −19.70% | ▼ −17.14% | $1.59 (+20.45%) |
May 4, 2026 25w ago | 8-K | $3.68 $3.48 | ▼ −5.43% | ▼ −8.37% | $1.59 (−56.79%) |
Apr 20, 2026 27w ago | DEFA14A | $4.25 $3.76 | ▼ −11.53% | ▼ −12.44% | $1.59 (−62.59%) |
Mar 17, 2026 32w ago | EFFECT | $4.11 $3.94 | ▼ −4.14% | ▼ −1.48% | $1.59 (−61.31%) |
Mar 10, 2026 33w ago | S-3 | $4.88 $4.01 | ▲ +17.83% | ▲ +15.64% | $1.59 (+67.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers